MA32764B1 - Inhibiteurs de l'intégrase du vih - Google Patents

Inhibiteurs de l'intégrase du vih

Info

Publication number
MA32764B1
MA32764B1 MA33804A MA33804A MA32764B1 MA 32764 B1 MA32764 B1 MA 32764B1 MA 33804 A MA33804 A MA 33804A MA 33804 A MA33804 A MA 33804A MA 32764 B1 MA32764 B1 MA 32764B1
Authority
MA
Morocco
Prior art keywords
hiv
compounds
inhibitors
antigrade
prophylaxis
Prior art date
Application number
MA33804A
Other languages
Arabic (ar)
English (en)
Inventor
Richard C A Isaacs
Wayne J Thompson
Peter D Williams
Dai-Shi Su
Shankar Venkatraman
Mark W Embrey
Thorsten E Fisher
John S Wai
David C Dubost
Richard G Ball
Eric J Choi
Tao Pei
Sarah L Trice
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of MA32764B1 publication Critical patent/MA32764B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01L—SEMICONDUCTOR DEVICES NOT COVERED BY CLASS H10
    • H01L2924/00—Indexing scheme for arrangements or methods for connecting or disconnecting semiconductor or solid-state bodies as covered by H01L24/00
    • H01L2924/0001—Technical content checked by a classifier
    • H01L2924/0002—Not covered by any one of groups H01L24/00, H01L24/00 and H01L2224/00

Abstract

L'INVENTION CONCERNE DES COMPOSÉS DE FORMULE (I) QUI SONT DES INHIBITEURS DE L'INTÉGRASE DU VIH ET DES INHIBITEURS DE LA RÉPLICATION DU VIH. DANS LA FORMULE (I), X1, X2, Y, R1A, R1B, R2 ET R3 SONT DÉFINIS DANS LA DESCRIPTION. CES COMPOSÉS SONT UTILES DANS LA PROPHYLAXIE OU LE TRAITEMENT D'UNE INFECTION PROVOQUÉE PAR LE VIH ET LA PROPHYLAXIE, LE TRAITEMENT OU LE RETARDEMENT DU DÉCLENCHEMENT OU DE LA PROGRESSION DU SIDA. LES COMPOSÉS SELON L'INVENTION SONT UTILISÉS POUR LUTTER CONTRE UNE INFECTION VIH ET LE SIDA SOUS FORME DESDITS COMPOSÉS EUX-MÊMES (OU D'HYDRATES OU DE SOLVATES DE CEUX-CI) OU DE LEURS SELS PHARMACEUTIQUEMENT ACCEPTABLES. CES COMPOSÉS ET LEURS SELS PEUVENT ÊTRE EMPLOYÉS EN TANT QU'INGRÉDIENTS DANS DES COMPOSITIONS PHARMACEUTIQUES, ÉVENTUELLEMENT COMBINÉS À D'AUTRES ANTIVIRAUX, IMMUNOMODULATEURS, ANTIBIOTIQUES OR VACCINS.
MA33804A 2008-10-06 2011-05-02 Inhibiteurs de l'intégrase du vih MA32764B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19527108P 2008-10-06 2008-10-06
PCT/US2009/059306 WO2010042391A2 (fr) 2008-10-06 2009-10-02 Inhibiteurs de l'intégrase du vih

Publications (1)

Publication Number Publication Date
MA32764B1 true MA32764B1 (fr) 2011-11-01

Family

ID=41682332

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33804A MA32764B1 (fr) 2008-10-06 2011-05-02 Inhibiteurs de l'intégrase du vih

Country Status (22)

Country Link
US (2) US8513234B2 (fr)
EP (1) EP2349276B1 (fr)
JP (2) JP4880097B1 (fr)
KR (1) KR20110066224A (fr)
CN (1) CN102239172A (fr)
AR (1) AR073769A1 (fr)
AU (1) AU2009302663B2 (fr)
BR (1) BRPI0920605A8 (fr)
CA (1) CA2738814C (fr)
CO (1) CO6382127A2 (fr)
CR (1) CR20110184A (fr)
DO (1) DOP2011000093A (fr)
EA (1) EA201170537A1 (fr)
EC (1) ECSP11010959A (fr)
IL (1) IL212019A0 (fr)
MA (1) MA32764B1 (fr)
MX (1) MX2011003637A (fr)
NI (1) NI201100069A (fr)
PE (1) PE20110344A1 (fr)
TW (1) TW201020251A (fr)
WO (2) WO2010042392A2 (fr)
ZA (1) ZA201102620B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8283366B2 (en) 2010-01-22 2012-10-09 Ambrilia Biopharma, Inc. Derivatives of pyridoxine for inhibiting HIV integrase
WO2014008636A1 (fr) * 2012-07-11 2014-01-16 Merck Sharp & Dohme Corp. Composés macrocycliques en tant qu'inhibiteurs de l'intégrase du vih
CN102936188B (zh) * 2012-11-19 2015-07-15 湖北吉和昌化工科技有限公司 一种丙炔醇缩水甘油醚的合成方法
US9493479B2 (en) 2013-04-16 2016-11-15 Merck Sharp & Dohme Corp. Substituted pyrido[1,2-a]pyrazines as HIV integrase inhibitors
CN107722106A (zh) * 2016-08-11 2018-02-23 重庆大学 Hiv抑制剂
JP7181470B2 (ja) 2018-02-08 2022-12-01 株式会社ソシオネクスト 加算回路、受信回路及び集積回路
UA127822C2 (uk) 2019-03-22 2024-01-10 Гіліад Сайєнсіз, Інк. Місткові трициклічні карбамоїлпіридонові сполуки та їх фармацевтичне застосування
US11697652B2 (en) 2020-02-24 2023-07-11 Gilead Sciences, Inc. Tetracyclic compounds and uses thereof
CN111454214B (zh) * 2020-05-27 2023-04-07 龙曦宁（上海）医药科技有限公司 一种2-甲氧基1-嘧啶乙胺盐酸盐的合成方法
SI4196479T1 (sl) 2021-01-19 2024-01-31 Gilead Sciences, Inc. Substituirane piridotriazinske spojine in njihove uporabe

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003016275A1 (fr) * 2001-08-10 2003-02-27 Shionogi & Co., Ltd. Agent antiviral
PT1441734E (pt) * 2001-10-26 2007-05-31 Isti Di Ric Di Bio Moleco P An Di-hidroxipirimidinocarboxamidas inibidoras da integrase do vih
RS51542B (sr) * 2001-10-26 2011-06-30 Istituto Di Ricerche Di Biologia Molecolare P.Angeletti Spa. N-supstituisani hidroksipirimidinon karboksamidni inhibitori hiv integraze
AU2003216049B2 (en) * 2002-01-17 2008-07-17 Merck Sharp & Dohme Corp. Hydroxynaphthyridinone carboxamides useful as HIV integrase inhibitors
BR0317749A (pt) * 2002-12-27 2005-11-22 Angeletti P Ist Richerche Bio Composto, composição farmacêutica, e, uso de um composto
WO2004062613A2 (fr) * 2003-01-13 2004-07-29 Bristol-Myers Squibb Company Inhibiteurs d'integrase hiv
US7037908B2 (en) * 2003-04-24 2006-05-02 Bristol-Myers Squibb Company HIV integrase inhibitors
TW200510425A (en) * 2003-08-13 2005-03-16 Japan Tobacco Inc Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
AR046938A1 (es) 2003-12-12 2006-01-04 Merck & Co Inc Procedimiento para preparar hexahidropirimido[1,2-a]azepin-2-carboxilatos y compuetos similares
TW200526635A (en) * 2003-12-22 2005-08-16 Shionogi & Co Hydroxypyrimidinone derivative having HIV integrase inhibitory activity
ES2318478T3 (es) * 2004-04-06 2009-05-01 Novartis Vaccines And Diagnostics, Inc. Inhibidores de quinesina mitotica.
US7273859B2 (en) * 2004-05-12 2007-09-25 Bristol-Myers Squibb Company HIV integrase inhibitors: cyclic pyrimidinone compounds
US7115601B2 (en) * 2004-05-18 2006-10-03 Bristol-Myers Squibb Company HIV integrase inhibitors
US7176196B2 (en) * 2004-05-28 2007-02-13 Bristol-Myers Squibb Company Bicyclic heterocycles as HIV integrase inhibitors
US7192948B2 (en) * 2004-05-28 2007-03-20 Bristol-Myers Squibb Company Bicyclic heterocycles as HIV integrase inhibitors
US7157447B2 (en) * 2004-05-28 2007-01-02 Bristol-Myers Squibb Company Bicyclic heterocycles as HIV integrase inhibitors
US7173022B2 (en) * 2004-05-28 2007-02-06 Bristol-Myers Squibb Company Bicyclic heterocycles as HIV integrase inhibitors
WO2006060225A2 (fr) * 2004-11-23 2006-06-08 Merck & Co., Inc. Processus destine a la synthese asymetrique d'hexahydropyrimido[1,2-a] azepine-2-carboxamides et de composes correspondants
AU2006228278C1 (en) * 2005-03-31 2011-06-23 Msd Italia S.R.L. HIV integrase inhibitors
US7494984B2 (en) * 2005-08-31 2009-02-24 Bristol-Myers Squibb Company Substituted imidazo[1,2-a]pyrimidines as HIV viral DNA integrase inhibitors
WO2007059125A2 (fr) * 2005-11-15 2007-05-24 Bristol-Myers Squibb Company Inhibiteurs de l'integrase du vih
WO2007058646A1 (fr) 2005-11-15 2007-05-24 Bristol-Myers Squibb Company Inhibiteurs d’integrase du vih : composes cycliques de la pyrimidinone
US7902182B2 (en) * 2005-11-16 2011-03-08 Bristol-Myers Squibb Company HIV integrase inhibitors
US8039458B2 (en) * 2005-11-17 2011-10-18 Bristol-Myers Squibb Company HIV integrase inhibitors
WO2007064316A1 (fr) 2005-11-30 2007-06-07 Bristol-Myers Squibb Company Heterocycles bicycliques en tant qu'inhibiteurs de l'integrase du vih
US7897593B2 (en) * 2006-05-30 2011-03-01 Bristol-Myers Squibb Company HIV integrase inhibitors
US7893055B2 (en) * 2006-06-28 2011-02-22 Bristol-Myers Squibb Company HIV integrase inhibitors

Also Published As

Publication number Publication date
EP2349276B1 (fr) 2019-11-27
DOP2011000093A (es) 2011-07-15
BRPI0920605A8 (pt) 2016-04-26
CR20110184A (es) 2011-06-08
NI201100069A (es) 2012-08-08
BRPI0920605A2 (pt) 2015-12-22
WO2010042391A3 (fr) 2010-06-03
WO2010042391A2 (fr) 2010-04-15
US20100087419A1 (en) 2010-04-08
AU2009302663B2 (en) 2012-11-08
JP5600311B2 (ja) 2014-10-01
US8513234B2 (en) 2013-08-20
AR073769A1 (es) 2010-12-01
CN102239172A (zh) 2011-11-09
CO6382127A2 (es) 2012-02-15
MX2011003637A (es) 2011-04-27
CA2738814A1 (fr) 2010-04-15
KR20110066224A (ko) 2011-06-16
AU2009302663A1 (en) 2010-04-15
CA2738814C (fr) 2014-01-28
ECSP11010959A (es) 2011-05-31
PE20110344A1 (es) 2011-06-22
JP4880097B1 (ja) 2012-02-22
ZA201102620B (en) 2011-12-28
JP2012504648A (ja) 2012-02-23
WO2010042392A2 (fr) 2010-04-15
EA201170537A1 (ru) 2011-12-30
TW201020251A (en) 2010-06-01
EP2349276A2 (fr) 2011-08-03
WO2010042392A3 (fr) 2010-06-03
JP2012036207A (ja) 2012-02-23
US20130338141A1 (en) 2013-12-19
IL212019A0 (en) 2011-06-30

Similar Documents

Publication Publication Date Title
MA32764B1 (fr) Inhibiteurs de l'intégrase du vih
MA31036B1 (fr) Inhibiteurs non nucleosidiques de la transcriptase inverse
MA29745B1 (fr) Inhibiteurs de la transcriptase inverse du vih
MX2019007262A (es) Compuestos antivirales de bencilamina fosfodiamida.
MA34170B1 (fr) Inhibiteurs de transcriptase inverse non nucléosidiques
MA44674B1 (fr) Inhibiteurs de bromodomaine
MX2021013075A (es) Oxisteroles y metodos de uso de los mismos.
TN2011000316A1 (fr) Derives de sulfonamides
MA42410B1 (fr) Oxystérols et leurs méthodes d'utilisation
TN2009000450A1 (fr) Derives de pyridine
MA31754B1 (fr) Cis-imidazolines chirales
TNSN07022A1 (fr) Derives de pyridine
WO2009146555A8 (fr) Inhibiteurs de l'intégrase du vih, issus de la pyridoxine
MA28270A1 (fr) Pyrido [2, 3-D] pyrimidine-2, 4-diamines servant d'inhibiteurs de PDE 2
WO2005086700A3 (fr) Inhibiteurs de l'integrase du vih
TNSN08139A1 (fr) Composes therapeutiques
MA40225B1 (fr) Composés dihydroisoquinolinone substitués
MA54653B1 (fr) Modulateurs du récepteur de cxcr7 pipéridine
WO2008132138A9 (fr) Dérivés d'aminopyrimidines disubstituées en 4 et en 6
WO2005110414A3 (fr) Inhibiteurs de l'integrase du vih
EA200870577A1 (ru) Конденсированные трициклические сульфонамидные ингибиторы гамма-секретазы
MA46229B1 (fr) Composés d'hétéroaryle carboxamide en tant qu'inhibiteurs de ripk2
MA41633B1 (fr) Composés amide en tant qu'agonistes du récepteur 5-ht4
ATE517899T1 (de) Hiv-integrasehemmer
MA42769B1 (fr) Dérivés de fluoroindole en tant que modulateurs allostériques positifs du récepteur muscarinique m1